Pivotal Research Reaffirms Buy Rating for USANA Health Sciences (USNA)

Share on StockTwits

Pivotal Research restated their buy rating on shares of USANA Health Sciences (NYSE:USNA) in a research report released on Wednesday morning, AnalystRatings.com reports. Pivotal Research currently has a $105.00 price objective on the stock.

“We remain bullish on the prospects for USANA. Our estimate goes to $5.30, up from $5.20 previously, our 2020 estimate which is a 53-week year, is unchanged at $6.25. We have noted that this weak 1Q would be exactly the type of event that would prompt more aggressive share repurchases – which are not built into guidance. USNA is likely to regain its double-digit top-line growth later this year, even with pressure from F/X. This is a good, innovative company that has strong growth characteristics – with the occasional hiccup. Our price target goes to $105 based on 16.8x 2020 EPS.”,” the firm’s analyst commented.

Separately, Tigress Financial initiated coverage on USANA Health Sciences in a research note on Tuesday, April 16th. They set a buy rating on the stock.

Shares of USNA stock traded down $4.06 during mid-day trading on Wednesday, hitting $87.28. 8,468 shares of the company’s stock were exchanged, compared to its average volume of 204,867. USANA Health Sciences has a fifty-two week low of $75.27 and a fifty-two week high of $137.95. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 16.84 and a beta of 0.30.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, April 30th. The company reported $1.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.02. USANA Health Sciences had a return on equity of 29.03% and a net margin of 10.38%. The firm had revenue of $272.90 million for the quarter, compared to analysts’ expectations of $272.20 million. During the same quarter last year, the firm earned $1.19 earnings per share. The firm’s revenue for the quarter was down 6.5% compared to the same quarter last year. As a group, sell-side analysts forecast that USANA Health Sciences will post 5.18 EPS for the current year.

In other news, Director Myron W. Wentz sold 9,355 shares of USANA Health Sciences stock in a transaction dated Monday, February 4th. The stock was sold at an average price of $115.77, for a total transaction of $1,083,028.35. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert A. Fuller sold 282 shares of USANA Health Sciences stock in a transaction dated Monday, February 11th. The stock was sold at an average price of $110.20, for a total value of $31,076.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,564 shares of company stock worth $6,990,279. 42.50% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in USNA. Vanguard Group Inc. increased its holdings in USANA Health Sciences by 10.7% in the third quarter. Vanguard Group Inc. now owns 1,245,807 shares of the company’s stock valued at $150,182,000 after buying an additional 120,709 shares during the last quarter. Kepos Capital LP bought a new stake in USANA Health Sciences in the third quarter valued at about $783,000. Vanguard Group Inc increased its holdings in USANA Health Sciences by 10.7% in the third quarter. Vanguard Group Inc now owns 1,245,807 shares of the company’s stock valued at $150,182,000 after buying an additional 120,709 shares during the last quarter. MERIAN GLOBAL INVESTORS UK Ltd increased its holdings in USANA Health Sciences by 27.9% in the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 235,867 shares of the company’s stock valued at $27,768,000 after buying an additional 51,401 shares during the last quarter. Finally, Martingale Asset Management L P increased its holdings in USANA Health Sciences by 38.3% in the fourth quarter. Martingale Asset Management L P now owns 47,315 shares of the company’s stock valued at $5,572,000 after buying an additional 13,103 shares during the last quarter. 53.36% of the stock is currently owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Recommended Story: Bear Market – How and Why They Occur

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Westlake Chemical  Upgraded at ValuEngine
Westlake Chemical Upgraded at ValuEngine
Morgan Stanley Reiterates “$84.00” Price Target for Exxon Mobil
Morgan Stanley Reiterates “$84.00” Price Target for Exxon Mobil
Tenax Therapeutics  versus Its Rivals Critical Contrast
Tenax Therapeutics versus Its Rivals Critical Contrast
Steelcase  Stock Rating Lowered by Zacks Investment Research
Steelcase Stock Rating Lowered by Zacks Investment Research
Consumer Edge Lowers Kellogg  to Underweight
Consumer Edge Lowers Kellogg to Underweight
Grana y Montero SAA  Stock Rating Upgraded by Zacks Investment Research
Grana y Montero SAA Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.